Delivery Order SPE2DB22D3016-SPE2DB26FAAF1
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $21,183.76 to AmerisourceBergen Drug Corp for the supply of Remicade 100 mg vials. This firm fixed-price contract, awarded on September 4, 2025, represents a non-competitive set-aside delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion...
- The Defense Logistics Agency awarded a delivery order valued at $12,029.28 to AmerisourceBergen Drug Corp for the supply of Remicade 100 mg vials. The contract is a firm fixed price delivery order with an ultimate completion date of September 22, 2025, and was competitively awarded without set-aside provisions. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $28,603.96 on July 29, 2025, for the supply of Remicade 100 mg vials, with a completion date of July 30, 2025. This is a firm fixed price delivery order with no set-aside designation, meaning it was awarded through open competition. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $15,359.26 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Remicade 100 mg vials, with an ultimate completion date of September 22, 2025. This non-set-aside contract represents a competitive award to the pharmaceutical distributor and represents a continuation of AmerisourceBergen's role as a critical supplier of pharmaceutical products to the federal healthcare system. The work will be performed at AmerisourceBergen's...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $12,967.93 by the Defense Logistics Agency (DLA) on September 22, 2025, for the supply of Remicade 100 mg vials. The contract represents a firm fixed-price delivery order with an ultimate completion date of September 23, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation and is executed as a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $3,032.89 to AmerisourceBergen Drug Corp for the supply of Remicade 100 mg vials. The contract, awarded September 2, 2025, with an ultimate completion date of September 3, 2025, represents a firm fixed price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery at its corporate office location in...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $38,665.68 by the Defense Logistics Agency on August 27, 2025, for the supply of Remicade 100 mg vials. This is a firm fixed-price delivery order with no set-aside designation, awarded through open competition. The product will be performed at the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 28, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $17,318.52 to AmerisourceBergen Drug Corp for the supply of Remicade 100 mg vials, with an ultimate completion date of August 8, 2025. This competitively awarded, firm fixed-price delivery order was issued under a non-set-aside procurement and reflects the agency's ongoing pharmaceutical supply needs for military healthcare operations. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,669.41 to AmerisourceBergen Drug Corp for the supply of Remicade 100 mg vials, with an ultimate completion date of September 23, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under the company's existing Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a $18,837.70 delivery order on August 19, 2025, for the supply of Remicade 100 mg vials, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- SPE2DB22D3016Indefinite Delivery Contract
- SPE2DB22D3016-SPE2DB26FAAF1Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,495.88 to AmerisourceBergen Drug Corp for the supply of Remicade 100 mg vials. This competitively awarded, firm fixed-price contract was executed on October 20, 2025, with an ultimate completion date of October 21, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a potential value of $999,999,999 through December 2026 and serves as a comprehensive global pharmaceutical support vehicle for military healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, supplies an extensive portfolio of pharmaceuticals and medical commodities to support Defense Health Agency and other military healthcare programs worldwide. The company's substantial IDC with DLA enables it to deliver a wide range of pharmaceutical products across multiple therapeutic domains through flexible delivery orders such as this one for Remicade, a biologic immunosuppressant commonly used for rheumatoid arthritis and other inflammatory conditions. No set-aside designation was applied to this award, reflecting AmerisourceBergen's competitive capability in federal procurement.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.5k | 10/20/25 |